GSK sees blockbuster potential in targeted cancer therapy after promising early data

By Bhanvi Satija LONDON, April 12 (Reuters) - British drugmaker GSK's experimental targeted cancer drug Mo-rez has blockbuster potential, its head of oncology research has told reporters, after early data showed the drug helped shrink tumors in patients with advanced, hard-to-treat cancers. "This is one of our priority assets at this stage," GSK's Hesham Abdullah said on a call with journalists